JP2021524256A5 - - Google Patents

Info

Publication number
JP2021524256A5
JP2021524256A5 JP2020565492A JP2020565492A JP2021524256A5 JP 2021524256 A5 JP2021524256 A5 JP 2021524256A5 JP 2020565492 A JP2020565492 A JP 2020565492A JP 2020565492 A JP2020565492 A JP 2020565492A JP 2021524256 A5 JP2021524256 A5 JP 2021524256A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565492A
Other languages
English (en)
Japanese (ja)
Other versions
JP7489922B2 (ja
JP2021524256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/088013 external-priority patent/WO2019223733A1/en
Publication of JP2021524256A publication Critical patent/JP2021524256A/ja
Publication of JP2021524256A5 publication Critical patent/JP2021524256A5/ja
Priority to JP2024022697A priority Critical patent/JP2024056938A/ja
Application granted granted Critical
Publication of JP7489922B2 publication Critical patent/JP7489922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565492A 2018-05-23 2019-05-22 抗ox40抗体及び使用方法 Active JP7489922B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024022697A JP2024056938A (ja) 2018-05-23 2024-02-19 抗ox40抗体及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/088101 2018-05-23
CN2018088101 2018-05-23
PCT/CN2019/088013 WO2019223733A1 (en) 2018-05-23 2019-05-22 Anti-ox40 antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024022697A Division JP2024056938A (ja) 2018-05-23 2024-02-19 抗ox40抗体及び使用方法

Publications (3)

Publication Number Publication Date
JP2021524256A JP2021524256A (ja) 2021-09-13
JP2021524256A5 true JP2021524256A5 (cg-RX-API-DMAC7.html) 2022-05-23
JP7489922B2 JP7489922B2 (ja) 2024-05-24

Family

ID=68615676

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565492A Active JP7489922B2 (ja) 2018-05-23 2019-05-22 抗ox40抗体及び使用方法
JP2024022697A Withdrawn JP2024056938A (ja) 2018-05-23 2024-02-19 抗ox40抗体及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024022697A Withdrawn JP2024056938A (ja) 2018-05-23 2024-02-19 抗ox40抗体及び使用方法

Country Status (14)

Country Link
US (2) US12103974B2 (cg-RX-API-DMAC7.html)
EP (1) EP3797123A4 (cg-RX-API-DMAC7.html)
JP (2) JP7489922B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210013708A (cg-RX-API-DMAC7.html)
CN (1) CN112566935B (cg-RX-API-DMAC7.html)
AU (1) AU2019272384A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020023746A2 (cg-RX-API-DMAC7.html)
EA (1) EA202092460A1 (cg-RX-API-DMAC7.html)
IL (1) IL278772A (cg-RX-API-DMAC7.html)
MX (2) MX2020012567A (cg-RX-API-DMAC7.html)
SG (1) SG11202011024WA (cg-RX-API-DMAC7.html)
TW (1) TW202016133A (cg-RX-API-DMAC7.html)
WO (1) WO2019223733A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006931B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
WO2021098769A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
US20230011916A1 (en) * 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
CA3157319A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
WO2021098750A1 (en) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists
KR20220103709A (ko) * 2019-11-21 2022-07-22 베이진 엘티디 항-tigit 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법
EP4061850A4 (en) * 2019-11-21 2024-03-20 BeiGene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
EP4136116A4 (en) 2020-04-17 2024-06-19 Hutchison Medipharma Limited ANTI-OX40 ANTIBODIES AND USES THEREOF
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技(北京)有限公司 结合ox40的抗体或抗原结合片段
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
EP4475879A1 (en) 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2024141049A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗ox40抗体及其应用
WO2024184812A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 antibodies and methods of use
WO2024184810A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
TW202436345A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗cd3多特異性抗體及使用方法
IL324457A (en) 2023-05-12 2026-01-01 Genmab As Antibodies capable of binding to ox40, their variants and uses thereof
WO2024240247A1 (en) * 2023-05-25 2024-11-28 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies
CN122249464A (zh) 2023-11-30 2026-06-19 金麦安博股份有限公司 在组合疗法中的能够结合ox40的抗体

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
MX2009005189A (es) 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
EP2183254B1 (en) 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
PL2552961T3 (pl) * 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
LT2609118T (lt) * 2010-08-23 2017-04-25 Board Of Regents, The University Of Texas System Anti-ox40 antikūnai ir jų panaudojimo būdai
CN102010407A (zh) 2010-11-16 2011-04-13 上海科胜药物研发有限公司 一种合成达沙替尼的新方法
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
RS57840B1 (sr) * 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
SG11201607969XA (en) 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
TWI726608B (zh) * 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗-ox40抗體及其用途
CA2963974A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
PL3265123T3 (pl) * 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
JP6815329B2 (ja) 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ceacam6抗体およびその使用
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
WO2017063162A1 (zh) * 2015-10-15 2017-04-20 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
US10781260B2 (en) 2016-08-08 2020-09-22 Sorrento Therapeutics, Inc. Anti-OX40 binding proteins
MX2019002242A (es) 2016-08-26 2019-08-16 Beigene Ltd Anticuerpos anti-tim-3 y uso de los mismos.
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
CA3084394A1 (en) 2017-11-24 2019-05-31 Eucure (Beijing) Biopharma Co., Ltd Anti-ox40 antibodies and uses thereof
CN110092832B (zh) 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途
CN110467674B (zh) 2018-05-11 2022-05-31 同润澳门一人有限公司 抗ox40的全人抗体及其制备方法和用途
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
EP4061850A4 (en) 2019-11-21 2024-03-20 BeiGene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
WO2021098769A1 (en) 2019-11-21 2021-05-27 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
WO2021098750A1 (en) 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists
CA3157319A1 (en) 2019-11-21 2021-05-27 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
US20230011916A1 (en) 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
KR20220103709A (ko) 2019-11-21 2022-07-22 베이진 엘티디 항-tigit 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법

Similar Documents

Publication Publication Date Title
JP2024056938A5 (cg-RX-API-DMAC7.html)
US9180185B2 (en) Combination therapy of anti-HER3 antibodies
JP2021527431A5 (cg-RX-API-DMAC7.html)
JP2021524244A5 (cg-RX-API-DMAC7.html)
US8933202B2 (en) AXL antibodies
JP2019529373A5 (ja) 抗Tim−3抗体
JP2018534933A5 (cg-RX-API-DMAC7.html)
JP2016538876A5 (cg-RX-API-DMAC7.html)
JP2021510736A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
JP2020522280A5 (cg-RX-API-DMAC7.html)
JP2020515577A5 (cg-RX-API-DMAC7.html)
JP2020522281A5 (cg-RX-API-DMAC7.html)
JP2021525806A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2018533569A5 (cg-RX-API-DMAC7.html)
JP2022517216A5 (cg-RX-API-DMAC7.html)
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2021512652A5 (cg-RX-API-DMAC7.html)
CA3029977A1 (en) Antibodies with low immunogenicity and uses thereof
JP2024522075A5 (cg-RX-API-DMAC7.html)
JP2024519078A5 (cg-RX-API-DMAC7.html)
JP2025502061A5 (cg-RX-API-DMAC7.html)
JP2021528439A5 (cg-RX-API-DMAC7.html)